The purpose of this study is to assess the safety and tolerability of allogeneic mesenchymal stem / stromal cell therapy in individuals with chronic kidney disease.
Who can participate
Age range30 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age 30-80 years.
* Estimated glomerular filtration rate (eGFR) 25-55 ml/min/1.73m\^2
* Spot urine albumin:creatinine ≥30 mg/g unless on Renin-angiotensin-aldosterone system (RAAS) inhibition.
* Ability to give informed consent.
Exclusion Criteria:
* Hemoglobin A1c greater than or equal to 11%.(in individuals with diabetes mellitus)
* Anemia (hemoglobin less than 9g/dL)
* Body weight greater than 150 kg or BMI greater than 50
* Uncontrolled hypertension: sustained systolic blood pressure (SBP) greater than 155 mmHg at screening exam (a maximum of 3 screening visits will be allowed for demonstration of blood pressure control)
* Chronic hypotension: sustained SBP less than 85 mmHg at screening exam.
* Glomerulonephritis not in partial or complete remission for 6 months (or estimated/measured proteinuria greater than 10 grams/day)
* Active glomerulonephritis (glomerular disease) include: ANCA associated glomerulonephritis, post-infectious glomerulonephritis, lupus nephritis, amyloidosis, or other monoclonal gammopathy of renal significance.
* Nephrotic syndrome defined as proteinuria greater than 3.5g per 24 hours, plus hypoalbuminemia (serum albumin less than or equal to 2.5g/L) and edema
* Autosomal dominant or recessive polycystic kidney disease
* Kidney failure requiring renal replacement therapy (hemodialysis, peritoneal dialysis, or kidney transplantation)
* Active immunosuppression therapy (including prednisone greater than or equal to 10mg daily)
…